The aim of this study was to determine cardiovascular (CV) risk factors (RFs) and target organ damage clustering in 21280 Greek hypertensives stratified by gender and age. Glycemic and lipid profile were determined, left ventricular mass index, estimated gromerular filtration rate (eGFR), 10-years CV risk according to Framingham risk score (FRS) and HeartScore (HS) were calculated. Only 10.2% of patients had no concomitant RFs, 53.1% had one (48.8% dyslipidemia, 3.4% smoking, 0.9% diabetes), 32.9% had two (26% dyslipidemia and smoking, 6.6% dyslipidemia and diabetes, 0.3% smoking and diabetes) and 3.7% had all four traditional RFs. Obesity was present in 30%, metabolic syndrome in 38%, low eGFR in 24% and left ventricular hypertrophy in 49%. Mean FRS risk was 35% for males, 24.1% for females whereas in high risk (420%) were 68.7 and 50.7%, respectively (Po0.0001). Mean HS risk was 8.4% for males, 6.2% for females whereas in high risk (45%) were 48.6 and 36.2%, respectively (Po0.0001). Age was correlated to pulse pressure, eGFR, left ventricular mass index and CV risk (Po0.0001). Ageing increased the risk difference between genders for total (P ¼ 0.001) but not for fatal events (P ¼ nonsignificant). In conclusion, as RFs cluster in hypertensives, CV risk calculation should guide treatment decisions.
Introduction
Arterial hypertension often coexists with other metabolic and cardiovascular (CV) risk factors (RFs), such as diabetes, obesity and dyslipidemia. Less than 20% of hypertension cases occur without one or more concomitant RFs according to recent and older studies in the US.
1,2 A cluster of X2 additional CV RFs occurs in about half of hypertensive persons. 2 The presence of RFs and target organ damage (TOD) should be ascertained to assess global CV risk and determine the urgency, intensity and type of treatment required. Among hypertensive persons, about 40% of coronary events in men and 68% in women, are attributed to the clustering of two or more additional RFs. 2 Almost one in three US adults is obese; 3 obesity is associated with increased mortality and is responsible for an estimated 111909 excess deaths per year. 4 It is estimated that 40% of US hypertensive patients also suffer from obesity and 15% also have diabetes; 5 in addition, 48% of hypertensive men and 61% of hypertensive women, also have hyperlipidemia. 6 The coexistence of hypertension, diabetes, hyperlipidemia and obesity has been referred to as cardiometabolic RF clusters. 7 Data from the GOOD survey across Europe indicate that many hypertensive patients have multiple cardiometabolic RFs with the prevalence higher in Central Europe and the Atlantic European Mainland compared with Northwest and Mediterranean regions. 8 Such epidemiologic data are not currently available in Greek patients diagnosed with arterial hypertension. Our study utilized a retrospective design to evaluate the prevalence of CV RFs and the total CV risk in the 'real-world' physician practice of hypertensive patients in Greece stratified by gender and age. Specifically, we sought to determine the frequency of clustering of traditional RFs (dyslipidemia, smoking, diabetes and obesity) and the frequency of TOD (left ventricular hypertrophy (LVH), renal impairment) among a cohort of 21280 urban Greek adult male and female hypertensives of all age groups.
Methods

Study population and design
This retrospective study comprised all Caucasian adult patients (X20 years) with essential uncomplicated hypertension who were referred or selfreferred to the outpatient hypertensive clinics of our institutions from 1985 to 2010. Patients with secondary hypertension, acute and chronic inflammatory disease, diabetes mellitus type 1, malignancy, chronic obstructive pulmonary disease, renal failure (plasma creatinine 41.5 mg dl À1 in males, 41.4 mg dl À1 in females), heart failure, recent (o6 months) cerebrovascular event, coronary artery disease (history of stable, unstable angina or past myocardial infarction), ventricular arrhythmias, as well as pregnant females were excluded from the study.
Overall, 21280 Caucasian adult hypertensive patients of all age groups participated in the study, which was conducted in accordance with the Declaration of Helsinki 9 and was approved by the ethics committee of our institutions. Patients under antihypertensive medical treatment (42.8%) or hypolipidemic medication (3.9%) underwent wash out for at least 15 days. The following procedures were then carried out to all participants in order to define the existence of arterial hypertension and the clustering of other RFs and TOD: medical history, physical examination, repeated blood pressure (BP) measurements, determination of anthropometric characteristics, laboratory evaluation, complete echocardiographic study.
Anthropometric measurements
For each patient, weight, height, waist (W) and hip (H) circumference were measured. Waist circumference was measured at the midpoint between the bottom of the rib cage and above the top of the iliac crest from patients at minimal respiration to the nearest 0.1 cm. Waist to hip circumference ratio, body mass index and body surface area were also calculated (body mass index ¼ weight/height 2 , Du Bois formula for body surface area).
Laboratory measurements
Blood samples were collected from all patients from an antecubital vein between 0800 and 1000 hours, in a sitting position, after 12 h of fasting and avoiding alcohol (only water was allowed). Centrifugation and serum collection for laboratory analysis was completed immediately after admission. Parameters concerning glycemic/lipid profile and kidney function were measured. Specifically, serum glucose (Glu), total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A 1 , apolipoprotein B, plasma renin activity, albumin, creatinine and blood urea nitrogen were measured. HDL was determined after precipitation of the apolipoprotein B-containing lipoproteins with dextranmagnesium-chloride. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. 10 Estimated gromerular filtration rate (eGFR) was calculated using the MDRD (Modification of Diet in Renal Disease) formula.
11
Biochemical exams were carried out following standardized protocol 12 using a chromatographic enzymic method in a Technicon automatic analyser RA-1000 (Dade Behring, Marburg, Germany).
Echocardiographic study
Standard transthoracic echocardiographic examination was carried out in a dimly light room using certified equipment. The two-dimensional guided M-mode echocardiographic study of the left ventricle (LV) was performed at the parasternal longaxis view, and LV end-systolic and end-diastolic dimensions, as well as posterior wall and interventricular septum thicknesses, were measured as the mean from five consecutive cardiac cycles, according to the ASE/EAE recommendations. 13 LV mass was calculated using the method of Devereux et al. 13 and normalized for body surface area to obtain LV mass index.
Definitions
Hypertension was defined, according to the JNC7 and the ESH/ESC guidelines, [14] [15] [16] using the average (BP) 4140/90 mm Hg on at least three different office visits, or the presence of antihypertensive treatment. At each visit, office BP was measured as the average of three consecutive measurements with 1-min intervals and with the patient resting comfortably, back supported in the sitting position with the arm at the heart level, after a 15-min relaxation period. A mercury sphygmomanometer was used for all measurements, with a medium/large size cuff. Patients with borderline office BP were subjected to 24-h ambulatory BP monitoring on the non-dominant arm using a Spacelabs 90207 device (SpaceLabs, Redmond, WA, USA). Recordings were obtained during a working day with automatic readings at 15-min intervals during the daytime and at 30-min intervals during the night time. BP thresholds for definition of hypertension were 130/ 80 mm Hg (for 24-h), 135/85 (for daytime) and 120/ 70 mm Hg (for night time).
Metabolic syndrome was defined using the Adult Treatment Panel III (ATP III) criteria, 17 by the presence, in addition to hypertension, of two or more of the following criteria: (1) abdominal obesity: waist circumference 4102 cm in males and 488 cm in females; (2) Total 10-year CV risk was calculated using the Framingham risk score (FRS) and the Greek version of HeartScore (HS), as recommended by ACC/AHA guidelines. 18 FRS refers to the 10-years risk for CV events (coronary heart disease, stroke, peripheral artery disease and heart failure) and is considered high if 420%.
19 HS refers to the 10-years risk for fatal CV events and is considered high if 45%.
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Algorithms for FRS and HS calculation take into account traditional RFs (age, sex, systolic BP, total cholesterol and smoking are parameters used in algorithms of both scores whereas HDL, presence of diabetes mellitus or/and antihypertensive treatment are used only in FRS). 19, 20 Statistical analysis Continuous variables are presented as mean±1 s.d. and categorical variables as observed number (n, % 
Results
For this analysis of RFs clusters, the cohort included 21280 hypertensive patients (53.1% males). Mean age was 57.6 years (56.1 for males, 59.2 for females). Mean office BP was 165.1/100.4 mm Hg (164.1/101.7 for males, 166.2/99.0 for females), mean office heart rate was 74.3 bpm (73.7 for males, 74.9 for females) whereas the mean duration of hypertension was 28.3 months. As presented in Tables 1 and 2 , the mean CV risk, according to FRS, was 29.9% (35% for males, 24.1% for females). High-risk patients (FRS420%) were 60.2% of the total population (68.7% of males, 50.7% of females). According to HS, the mean CV risk was 7.4% (8.4% for males, 6.2% for females). High-risk patients (HS45%) were 42.8% of the studied population (48.6% of males, 36.2% of females) (Po0.001 for all).
Clusters of traditional RFs is depicted in Figure 1 . Of the 21280 patients, only 2172 (10.2%) had no additional RFs. More than half (53.1%) of the study cohort had one concomitant RF (48.8% had dyslipidemia, 3.4% were current smokers whereas 0.9% had type 2 diabetes mellitus). One out of three patients (32.9%) had two additional RFs (26% dyslipidemia and smoking, 6.6% dyslipidemia and diabetes, 0.3% smoking and diabetes). The remaining 3.7% of patients studied had all four traditional RFs (hypertension, dyslipidemia, smoking and diabetes). Overall, dyslipidemia was present in 85% of patients, smoking in 33%, type 2 diabetes mellitus in 12%, impaired fasting glucose in 18% and impaired glucose tolerance in 16%. In total, 46% of the participants had impaired glucose metabolism. Furthermore, obesity was present in 30%, metabolic syndrome in 38%, low eGFR in 24% and LVH in 49% of all patients.
The study population was divided in 5-years age groups. RF and CV risk values for all groups are presented in Table 1 . Global CV risk was greater in males for all age groups (Po0.0001). Even in late life, females seem to be in lower CV risk (Table 1, Figure 2 ).
The prevalence of each RF according to gender and age is presented in Table 2 . Smoking, type 2 diabetes mellitus, impaired fasting glucose, low HDL and high TG and total CV risk were present more often in males, whereas females suffered more often from obesity, impaired glucose tolerance, metabolic syndrome, LVH, low eGFR and high total cholesterol, LDL and apolipoprotein B (Po0.0001 for all).
The relation of age to RFs and CV risk is presented in Table 3 . In both genders, as expected, there was a strong positive correlation between age and systolic BP, pulse pressure (stronger than this for systolic BP), left ventricular mass index and CV risk and a good negative relationship between age and diastolic BP and eGFR. Correlation of age to remaining RFs, though statistically significant, was weaker.
Total CV risk for males and females in the various age groups is shown in Figure 2 . Ageing seems to ; TOD, target organ damage; mWHR, waist to hip ratio 40.9
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for males and 40.8
for females.
a Expressed in years.
increase the difference between genders in the risk for total CV events (according to FRS) but less so for fatal CV events (according to HS). Especially, in patients over 60 years old the difference in the risk for total CV events between genders correlated strongly with age (r ¼ 0.980, P for trend ¼ 0.001) whereas the difference in the risk for fatal CV events between genders did not have a significant relationship with age (r ¼ 0.134, P ¼ nonsignificant).
The influence of postmenopausal estrogens' loss on CV risk in females is also apparent in this study. Specifically, in the age spectrum 45-54 years, postmenopausal women (n ¼ 1271, mean age ¼ 51.0) had an elevated mean CV risk (Po0.0001) compared with premenopausal females (n ¼ 1076, mean age ¼ 49.0 years) even after adjustment for age (16.9 versus 13.8% according to FRS and 1.1 versus 0.7% according to HS).
Discussion
To our knowledge, the present study is the first large-scale study to assess the clustering of CV RFs stratified by gender and age in a large urban population (21280 participants) of Greek hypertensive patients, which is indicative of the 'real-world' situation in Greece. According to the results of this study, almost 9 out of 10 patients of our hypertensive study population had one or more additional RFs. Mean CV risk (as calculated both with FRS and HS) was high (420 and 45%, respectively). Ageing does not seem to equalize CV risk between the two genders. Although prevalence of most RFs is higher in females, their CV risk is lower compared with males, pointing out the necessity of incorporating additional parameters in the algorithms of risk assessment. Besides, CV risk was found to be better correlated to pulse pressure than either systolic or diastolic BP in both genders.
The results of this study seem to be in agreement with the current literature. In a recent similar crosssectional study among 28 physician practices in the United States, Belleti et al. 1 found that most (82%) of the 6527 studied hypertensive patients had one or more additional cardiometabolic RFs: 61% had dyslipidemia, almost half (49%) were obese and one out of four (25%) had diabetes whereas 12.2% had all three RFs. With the exception of patients with only hypertension and dyslipidemia, patients with one or more RFs were less likely to have controlled BP. The odds of BP control for hypertensive patients with all three cardiometabolic RF clusters were 23% of the odds of control for hypertensive patients without RFs. According to the GOOD survey, 8 type 2 diabetes was present in 26%, metabolic syndrome in 52% and uncontrolled BP in 70% of Mediterranean hypertensive patients.
The high prevalence of cardiometabolic RF clusters in hypertensive patients presents a challenge to the management of BP, and should be considered when selecting the most appropriate antihypertensive agent, with consideration given to both specific medication classes, as well as the overall intensity of the therapeutic regimen. More aggressive hypertension management strategies for obese and/or diabetic hypertensive patients are warranted to improve BP control in these difficult-to-treat patient subgroups.
Although our study provides useful information about the prevalence of CV RFs and their impact on hypertension management, it is important to consider several limitations. Patients in this study came mostly from Athens (a large city) representing basically an urban population. Other regions of the country (for example islands, north part of Greece) are less so represented. Residents of these regions may have a different life style that may alter CV risk and the prevalence of CV RFs. Thus, it should be clear that this study is mostly applicable to Athens and the other large cities and not so much to agricultural regions of the country. On the other hand, almost half of the total Greek population is gathered in Athens whereas western dietary habits have been adopted from the majority of the population. Based on these points, the results of this study are indicative of the situation in the whole hypertensive population.
Conceptual limitations should also be mentioned. Total CV risk is highly dependent on age. Thus, in young patients absolute total CV risk can be low even in the presence of high BP with additional RFs. If ineffectively treated, however, this condition may lead to a partly irreversible high-risk condition years later. In younger subjects, treatment decisions should better be guided by quantification of relative risk, that is, the increase in risk in relation to average risk in the total population. This is possible with the HeartScore management tool with the update provided by the guidelines on CV disease prevention in clinical practice issued by the Fourth Joint European Task Force. 21 Moreover, the age spectrum of the studied population in the Framingham study 19 (in which FRS is based) was 30-74 years whereas in the SCORE project 20 (in which HS is based) was 40-64 years. Thus, it is recommended to use these algorithms only in patients of these age spectrums. Furthermore, extreme values (o1 or 430% for FRS Moreover, all currently available models for CV risk assessment do not consider the duration of exposure to a RF or disease and their quantification is usually based on some RFs only, while paying limited attention to other variables linked to CV outcome (for example, physical activity, stress, abdominal obesity, LVH, TG, family history of premature CV disease). 19, 22 One should not forget that stratification of absolute risk is often used by private or public healthcare providers to establish a barrier below which treatment is discouraged. The threshold of 20% risk of CV disease in 10 years is arbitrary and simplistic, and use of a cutoff value leading to intense interventions above this threshold and no action at all below cannot be supported. One should be aware of the strong effect of age on total CV risk models. It is so strong that younger adults (particularly women) are unlikely to reach high-risk levels even when they have more than one major RF and a clear increase in relative risk (that is the existing risk compared with their peers). In contrast, most elderly men (for example, 470 years) will often reach a high total risk level while being at very little increased risk relative to their peers.
Other potential factors, including the duration or etiology of hypertension, the duration of antihypertensive medication use, the impact of the pharmacological wash out, the previous antihypertensive medication failure, the seasonal effects on BP, the fact that our patient sample is a healthcare-seeking population and the type of health insurance coverage were not taken into account for the analysis in this study.
Conclusions
Dysmetabolic RFs and subclinical TOD are common in Greek hypertensives. All patients should be classified in terms of the total CV risk resulting from the coexistence of additional RFs, organ damage and disease. Decisions on treatment strategies all importantly depend on the initial level of risk.
Hypertension should be regarded not as a simple elevation of BP, but as a constellation of functional and structural abnormalities that create a phenotypic portrait of hypertensive disease. Recent research has expanded our knowledge related to hypertensive heart disease. [23] [24] [25] [26] Future assessment of hypertensive patients global risk should probably incorporate not only evaluation of the known traditional RFs but also myocardial fibrosis, microvascular ischemia, arterial stiffness, systemic inflammation, endothelial dysfunction and level of apoptosis.
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